A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
ApexOnco Front Page
Recent articles
So who else could be interested in the oestrogen degrader?
The company reckons its immunotherapy could improve on Keytruda.
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
Satri-cel is filed for gastric cancer approval in China.
“We need all the capital we can get our hands on," the company states.
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.
